Name:
Macacemten and the MAVERICK-HCM Trial
Description:
Macacemten and the MAVERICK-HCM Trial
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/03a41f15-4fe5-4d80-8ef3-2493ccf8c71b/thumbnails/03a41f15-4fe5-4d80-8ef3-2493ccf8c71b.jpeg?sv=2019-02-02&sr=c&sig=JNJOlVbAmUOF5QT91KS41oSu0Aa8Dwx9du%2Bq%2F2RgEw0%3D&st=2024-12-21T14%3A02%3A32Z&se=2024-12-21T18%3A07%3A32Z&sp=r
Duration:
T00H03M41S
Embed URL:
https://stream.cadmore.media/player/03a41f15-4fe5-4d80-8ef3-2493ccf8c71b
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/03a41f15-4fe5-4d80-8ef3-2493ccf8c71b/18777603.mp3?sv=2019-02-02&sr=c&sig=hLsNbooHJ%2FtvFTOGf%2FWpzr5bpsNHdKZjeRMR0w2QKeY%3D&st=2024-12-21T14%3A02%3A32Z&se=2024-12-21T16%3A07%3A32Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's The Heart Board Review, and other online resources available only through accesscardiology.com. >> Hypertrophic cardiomyopathy, as is well-known, is associated with increased mortality. Is there any new research that's being assessed that would provide options for different treatment for the disease particularly related to the underlying cause? [ Music ] >> Hi, Dr. Bernie here, and welcome to Practice Impact Extra.
Hypertrophic cardiomyopathy is a genetic heart muscle disease caused by a mutation in the gene encoding of sarcomere protein. This mutation in cardiac myosin seemed to increase the net power generation by sarcomeres and secondarily leads to clinically impaired compliance. There was a small trial of 21 patients in April of 2019, which assessed the new drug Mavacamten in patients with hypertrophic obstructive cardiomyopathy.
Mavacamten is the first in the class of cardiac-specific molecular modulators of B-cardiac myosin that reversibly inhibits its binding to actin, and thus normalizes the function of myosin. This was a Phase II trial but was limited by the small size and open label but suggested that Mavacamten did reduce LV obstruction, and some improvement in exercise reserve.
This March, in 2020, the MAVERICK hypertrophic cardiomyopathy trial was presented at the ACC. This again was a small Phase II trial that looked at the safety and tolerability of Mavacamten in patients with hypertrophic cardiomyopathy, not the obstructive group. Fifty-nine patients were enrolled and randomly assigned to target levels of Mavacamten, either a 200 or 500 nanograms per milliliter, and that was compared to placebo.
To be enrolled, patients had to have a Class II to III New York Heart Association congestive heart failure classification, and that would be either on a beta blocker or calcium channel blocker. Left Ventricular ejection fraction was 69% in the Mavacamten group and 66% in the control group. So really, what was noted that 16 weeks? The BNP levels, the troponin levels, also all decreased in the Mavacamten group with an 88% improvement in functional assess endpoint, a peak oxygen uptake, and at least one class improvement in congestive heart failure classification.
And this was best seen in those the most severe disease. So what's the take home message here? The MAVERICK-HCM trial has created some excitement particularly that it introduced an entirely new class of therapeutics for a problem that has very few options in the past, so stay tuned. Thanks for joining me and see you next time on Practice Impact Extra.
>> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to AccessCardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features. To subscribe or learn more, please visit accesscardiology.com.
